Prostate Cancer

Blue Earth Diagnostics Announces Efficacy and Safety Results from Phase 3 LIGHTHOUSE Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer December 2, 2022

Statin Use and Survival Among Men Receiving Androgen-Ablative Therapies for Advanced Prostate Cancer: A Systematic Review and Meta-analysis. December 2, 2022

Metabolic syndrome is associated with aggressive prostate cancer regardless of race. December 2, 2022

Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation. December 2, 2022

Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec. December 2, 2022

Impact of Race on Outcomes of High-Risk Patients With Prostate Cancer Treated With Moderately Hypofractionated Radiotherapy in an Equal Access Setting. December 2, 2022

Germline Variants in DNA Damage Repair Genes and HOXB13 Among Black Patients With Early-Onset Prostate Cancer. December 1, 2022

Acute effect of high-intensity interval aerobic exercise on serum myokine levels and resulting tumour-suppressive effect in trained patients with advanced prostate cancer. December 1, 2022

Modern Active Surveillance in Prostate Cancer: A Narrative Review. December 1, 2022

Feasibility of MRI targeted single fraction HDR brachytherapy for localized prostate carcinoma: ProFocAL-study. December 1, 2022

FACT SHEET: President Biden Details Cancer Moonshot Progress and New Initiatives on 60th Anniversary of President Kennedy’s Moonshot Address November 30, 2022

Exploring New Frontiers in Prostate Cancer Research: Report from the 2022 Coffey-Holden Prostate Cancer Academy Meeting November 30, 2022

Clinical Outcomes of First Subsequent Therapies After Abiraterone Acetate Plus Prednisone for High-Risk Metastatic Castration-Sensitive Prostate Cancer in the LATITUDE Study. November 30, 2022

Comparing symptom reporting by prostate cancer patients and healthcare professionals in the international multicentre REQUITE study. November 30, 2022

Retzius-sparing vs. standard robot-assisted radical prostatectomy for clinically localised prostate cancer: a comparative study. November 30, 2022

Late toxicity of moderately hypofractionated intensity-modulated proton therapy treating the prostate and pelvic lymph nodes for high-risk prostate cancer. November 30, 2022

A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer. November 30, 2022

Disparities in the Inclusion of Racial and Ethnic Minority Groups and Older Adults in Prostate Cancer Clinical Trials: A Meta-analysis. November 30, 2022

Variation in patient reported outcomes following radical prostatectomy: A bi-national registry-based study. November 29, 2022

Positive Prostate-specific Membrane Antigen Findings: How To Interpret Them. November 29, 2022

Page 1 of 1263

email news signup